Alturas Analytics provides LC-MS/MS services that help organizations make confident decisions during all stages of drug development. Our LC-MS/MS platforms generate precise and reliable submission-ready data for small-molecule and complex therapeutic programs during all stages from early-stage assay development to regulated clinical sample analysis.
Our quantitative expertise prepares your data for regulatory review when you are developing new chemical entities.

Our scientists assist your project throughout feasibility evaluation, formal method validation, and clinical execution. The LC-MS/MS services at Alturas include:
Learn More: Development and Validation of LC-MS/MS Methods
The laboratory at Alturas Analytics provides analytical support for various biological samples and chemical compounds. We provide:
Our team demonstrates exceptional ability to handle extraction variations and method transfers between development and regulated environments.
Our lab uses industry-standard instrumentation configured for accuracy, precision, and throughput.
Explore Our Tech Focus: Alturas Analytics Instrumentation
Alturas Analytics operates under GLP compliance and follows ICH M10 guidance for method validation and data reporting procedures. We offer:
Explore More: Alturas Analytics Quality
Related Project: GC-MS/MS Tuberculosa Case Study
Our HRMS capabilities support both qualitative and quantitative workflows—ideal for protein quantitation, metabolite identification, biomarker discovery, and non-targeted screening delivering precise mass accuracy and robust sensitivity to provide deeper insight across discovery and regulated studies.
The GC-MS/MS technology at Alturas Analytics delivers sensitive and selective detection methods for detecting volatile semi-volatile and thermally unstable compounds. Scientists from our team employ GC-MS/MS techniques when LC-MS/MS methods are inappropriate to achieve complete detection of substances across therapeutic programs.
The bioanalytical quantitative method of choice for analyzing diverse analytes includes high selectivity and sensitivity capabilities through liquid chromatography-tandem mass spectrometry (LC-MS/MS).
The M10 bioanalytical method validation guidance requires our laboratory to perform accuracy and precision, as well as selectivity, sensitivity, and reproducibility checks.
Yes. Bioanalytical data generated at Alturas is GLP-compliant and ready for submission to the FDA, EMA, and other regulatory bodies.
Need defensible, fast-turnaround LC-MS/MS support for your drug development program?
The first step to start a data-driven partnership with an Alturas Analytics scientist begins with requesting a consultation.
Method Development and Validation

Chad has over 24 years of related experience as an analytical scientist with over 20 years focused on bioanalysis at Alturas Analytics. Chad is responsible for supervision of the analytical method development team in supporting method validations and sample analysis and Study Director/Principal Investigator on GLP and clinical studies, providing technical oversight to clients across all therapeutic areas.
"*" indicates required fields